The inspection concluded with zero observations, confirming the facility's compliance with current Good Manufacturing Practices
Nadda underlined that India’s policy framework is aligned with this transformation
Backed by a multi-hundred-million-dollar investment, the expansion underscores Sanofi’s long-term commitment to India’s thriving life sciences ecosystem
BioAsia 2026 represents a decisive shift toward execution, scale, and global competitiveness, reflecting the rapid evolution of the life sciences ecosystem
Anand Chemiceutics serves over 1,500 laboratories, hospitals, and government institutions
Revenue from operations surged 30% year-on-year to Rs. 68,645 million
On segmental performance, API revenues were largely stable at Rs. 454.3 crore for Q3 FY26, down 1% YoY
The program seeks to boost regulatory predictability, support construction of US-based manufacturing sites
TB Alliance will continue to lead clinical development, while Lupin will leverage its global manufacturing, regulatory, and supply chain expertise to ensure the drug reaches patients worldwide
The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
